糖尿病慢性肾脏病早期患者继发性甲状旁腺功能亢进症的影响因素分析

Abstract
Figure/Table
References (22)
Related Citation (12)

Download: PDF (551 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective To analyze the influence factors on secondary hyperparathyroidism (SHPTH) in early stage patients with diabetic CKD, as to provide theoretical basis for clinical work. Methods All data of early stage patients admitted to 95th Hospital of PLA from July 2012 to July 2014 were retrospectively analyzed, and all patients were divided into combined with SHPTH group and not combined with SHPTH group according to whether the merger of SHPTH. General situation of two groups were analyzed, and at the same time, SHPTH was chosen as the dependent variable to analyze the multiple factors regression for patients with diabetic CKD. Results 481 patients were studied, in which, 214 cases (44.49%) was combined with SHPTH, 267 cases (55.51%) were not combined with SHPTH. The levels of hypertension, hyperlipidemia, serum phosphorus, 25-OH-VitD, urinary albumin and HbA1c between two groups were compared, with statistically significant differences (P < 0.05 or P < 0.01). Multivariate analysis showed that hypertension, hyperlipidemia, hyperphosphatemia, low 25-OH-VitD, high urinary microalbumin, high HbA1c and SHPTH had a certain relationship (P < 0.05). Conclusion Diabetic CKD patients whether combined with SHPTH is influenced by many factors, it can through reduce the patients' blood pressure, blood lipid, blood phosphorus, urine trace albumin, HbA1c level, improve 25-OH-VitD to improve the prognosis of patients.

Key words： Chronic kidney disease Secondary hyperparathyroidism Diabetes millitus Hypertension

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	YANG Qingbai JI Guoxin▲ CHEN Zhizhong HUANG Yuping CHEN Hong ZHANG Huimin

Cite this article:

YANG Qingbai JI Guoxin▲ CHEN Zhizhong HUANG Yuping CHEN Hong ZHANG Huimin. Influence factors analysis on secondary hyperparathyroidism in early stage patients with diabetic CKD[J]. 中国医药导报, 2017, 14(29): 125-127,136.

URL:

http://www.yiyaodaobao.com.cn/EN/ OR http://www.yiyaodaobao.com.cn/EN/Y2017/V14/I29/125

[1] National Kidney Foundation. K/DOQI clinical practice guidelines for chronic kidney disease：evaluation，classification，and stratification [J]. Am J Kidney Dis，2002，39（2 Suppl 1）：S1-S266.
[2] 杨莹.阿托伐他汀对慢性肾脏病患者肾功能的影响[J].中国当代医药，2015，22（32）：139-141.
[3] 陈左平.利拉鲁肽治疗2型糖尿病合并轻中度慢性肾脏病的有效性和安全性分析[J].中国当代医药，2016，23（30）：131-133.
[4] Collins AJ，Foley RN，Herzog C，et al. US renal data system 2010 annual data report [J]. Am J Kidney Dis，2011， 57（Suppl 1）：e1-e526.
[5] 王海燕.肾脏病学[M].3版.北京：人民卫生出版社，2008：1919-1931.
[6] 国家肾脏基金会.慢性肾脏病及透析的临床实践指南[M].王梅，王海燕，译.北京：人民卫生出版社，2003：130.
[7] 中国高血压防治指南修订委员会.中国高血压防治指南2010[J].中华高血压杂志，2011，19：701-744.
[8] 中国成人血脂异常防治指南修订联合委员会.中国成人血脂异常防治指南[J].中华心血管病杂志，2007，35（5）：390-341.
[9] Martinez-Castelao A，Gorriz JL，Portoles JM，et al. Baseline characteristics of patients with chronic kidney disease stage 3 and stage 4 in Spain：the MERENA observational cohort study [J]. BMC Nephrol，2011，12（1）：53.
[10] 施俊义.继发性甲状旁腺功能亢进的诊断与治疗[J].中国实用外科杂志，2008，28（3）：185-186.
[11] Grodin JL，Lala A，Stevens SR，et al. Clinical implications of serum albumin levels in acute heart failure：insights from dose-AHF and rose-AHF [J]. J Card Fail，2016，22（11）：884-890.
[12] Mawxwell CS，Wood R. Update on vitamin D and type 2 diabetes [J]. Nutr Rev，2011，69（5）：291-295.
[13] Gagnon C，Lu ZX，Magliano DJ，et al. Serum 25-hydroxyvitamin D，calcium intake and risk of type 2 diabetes after 5 years：results from a national population-based prospective study（the Australian diabetes，obesity and lifestyle study） [J]. Diabetes Care，2011，34（5）：1133-1138.
[14] Gradillas-García A，lvarez J，Rubio JA，et al. Relationship between vitamin D deficiency and metabolic syndrome in adult population of the Community of Madrid [J]. Endocrinol Nutr，2015，62（4）：180-187.
[15] Kositsawat J，Freeman VL，Gerber BS，et al. Association of A1C levels with vitamin D status in U.S. adults：data from the National Health and Nutrition Examination Surgery [J]. Diabetes Care，2010，33（6）：1236-1238.
[16] Uluogullari CA，Balkan F，Caner S，et al. The relationship between microvascular complications and vitamin D deficiency in type 2 diabetes mellitus [J]. BMC Endocr Disord，2015，15（29）：33.
[17] Tufan AN，Soyluk O，Tufan F. True vitamin D deficiency with secondary hyperparathyroidism [J]. J Rheumatol，2016， 43（11）：2078.
[18] Levin A，Bakris GL，Molitch M，et al. Prevalence of abnormal serum vitamin D，PTH，calcium and phosphorus in patients with chronic kidney disease：results of the study to evaluate early kidney disease [J]. Kid Intern，2007，71（1）：31-38.
[19] Baldane S，Ipekci SH，Evcen R，et al. A case of hypercalcaemic crisis secondary to coexistence of primary hyperparathyroidism and Graves' disease [J]. Endocr Regul，2016，50（4）：225-228.
[20] Chanchlani R，Ackerman S，Piva E，et al. Intraperitoneal calcitriol for treatment of severe hyperparathyroidism in children with chronic kidney disease：a therapy forgotten [J]. Perit Dial Int，2016，36（6）：688-690.
[21] ■iprová H，Sou■ek M，Fry■ák Z，et al. Symptomatic and asymptomatic primary hyperparathyroidism in outpatient care-current issues [J]. Vnitr Lek，2016，62（10）：775-780.
[22] Fernandes S，Almeida P，Melo-Gomes J，et al. Brown tumors in secondary hyperparathyroidism in a patient with lupus nephritis [J]. J Clin Rheumatol，2016，22（8）：438-439.